Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma

Jung-Hee Kwon1, Namgyu Lee2, Jin Young Park1, Yun Suk Yu1, Jin Pyo Kim1, Ji Hye Shin2, Dong-Sik Kim3, Jae Won Joh4, Dae Shick Kim5, Kwan Yong Choi2, Koo-Geong Kang6, Gundo Kim7, Young Ho Moon1*, Hee Jung Wang8

1 Cbs Bioscience Inc., Daejeon, Korea, 2 Department of Life Sciences, Pohang University of Science and Technology, Pohang, Korea, 3 Division of HBP Surgery & Liver Transplantation, Department of Surgery, Korea University College of Medicine, Seoul, Korea, 4 Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 5 Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 6 Department of Surgery, Keimyung University School of Medicine, Daegu, Korea, 7 Department of Microbiology, Pukyong National University, Busan, Korea, 8 Department of Surgery, Ajou University School of Medicine, Suwon, Korea

Abstract

Background: The effectiveness of molecular targeted agents is modest in hepatocellular carcinoma (HCC). Efficacy of molecular targeted therapies has been better in cancer patients with high expression of actionable molecules defined as cognate target molecules. However, patient stratification based on the actionable molecules dictating the effectiveness of targeted drugs has remained understudied in HCC.

Experimental Design & Results: Paired tumor and non-tumoral tissues derived from a total of 130 HCC patients were studied. Real-time RT-PCR was used to analyze the mRNA expression of actionable molecules in the tissues. mRNA levels of EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR were up-regulated in tumors compared to non-tumors in 35.4, 42.3, 61.5, 24.6, and 50.0% of patients, respectively. Up-regulation of EGFR was observed at early stage and tended to gradually decrease toward late stages (BCLC stage A: 41.9%; B: 30.8%; C: 17.6%). Frequency of VEGFR2 expression in tumors at stage C was lower than that in the other stages (BCLC stage A: 45.9%; B: 41.0%; C: 29.4%). PDGFRβ and mTOR were observed to be up-regulated in more than 50% of tumors in all the stages whereas FGFR1 was up-regulated in only about 20% of HCC irrespective of stages. A cluster analysis of actionable gene expression revealed that HCC can be categorized into different subtypes that predict the effectiveness of molecular targeted agents and combination therapies in clinical trials. Analysis of in vitro sensitivity to sorafenib demonstrated that HCC cells with up-regulation of PDGFRβ and c-Raf mRNA are more susceptible to sorafenib treatment in a dose and time-dependent manner than cells with low expression of the genes.

Conclusions: mRNA expression analysis of actionable molecules could provide the rationale for new companion diagnostics-based therapeutic strategies in the treatment of HCC.

Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. HCC is the sixth most common cancer and the third most common cause of cancer mortality in the world [1]. Many molecular targeted drugs have entered clinical trials as palliative and adjuvant treatments for HCC [2]. The multikinase inhibitor sorafenib was approved for the first-line therapy in advanced HCC as a result of a statistically significant but modest improvement of overall survival and time to progression in two randomized controlled trials [3,4]. Other molecular targeted drugs have been tested in combination with sorafenib or in the adjuvant setting [5,6]. However, the limited benefits of current molecular targeted agents including sorafenib have raised an urgent need for new therapeutic strategies in HCC [7].

Predictive biomarkers are increasingly used for diagnosis, prognosis, and therapeutic decision making in diverse cancers, propelling a paradigm shift in the management of cancer [8–10]. Biomarkers have helped to stratify patients and thus achieve better outcomes from a given drug in the clinic. Trastuzumb, a HER2 targeting monoclonal antibody, is effective in metastatic breast cancer patients with 3+ HER2 overexpression assessed by IHC or HER2 gene amplification [11]. Also, patients with non-small cell
In many kinds of cancer, the expression of actionable molecules has been shown to be aberrantly regulated. We therefore investigated mRNA expression for 5 actionable molecules (EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR) in 130 HCC and matched non-tumoral tissues. The average mRNA levels of EGFR were significantly higher in the tumors than in non-cancerous hepatic tissues (1.47 fold difference in mean copy number ratios, P = 0.002) (Fig. 1A). EGFR mRNA expression was increased in tumors diagnosed at BCLC stage A (1.64 fold, P = 0.002) and this expression pattern was maintained in BCLC stage B tumors (Fig. 1A). The mean expression of VEGFR2 was up-regulated in all tumors, but the expression difference was statistically significant only for BCLC stage A tumors (1.38 fold, P = 0.047; Fig. 1B). PDGFRβ mRNA was significantly overexpressed in all the tumors irrespective of BCLC stage (2.93, 3.29, 2.02, 3.41 fold in all tumors and BCLC stages A, B, and C, respectively; Fig. 1C). The differences in the FGFR1 mRNA levels between tumors and non-tumoral tissues were statistically significant only for BCLC stage A tumors (1.64 fold, P = 0.002) (Fig. 1A). 

Results

Expression of actionable molecules in the paired tissues of tumor and surrounding normal liver

In many kinds of cancer, the expression of actionable molecules has been shown to be aberrantly regulated. We therefore investigated mRNA expression for 5 actionable molecules (EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR) in 130 HCC and matched non-tumoral tissues. The average mRNA levels of EGFR were significantly higher in the tumors than in non-cancerous hepatic tissues (1.47 fold difference in mean copy number ratios, P = 0.002) (Fig. 1A). EGFR mRNA expression was increased in tumors diagnosed at BCLC stage A (1.64 fold, P = 0.002) and this expression pattern was maintained in BCLC stage B tumors (Fig. 1A). The mean expression of VEGFR2 was up-regulated in all tumors, but the expression difference was statistically significant only for BCLC stage A tumors (1.38 fold, P = 0.047; Fig. 1B). PDGFRβ mRNA was significantly overexpressed in all the tumors irrespective of BCLC stage (2.93, 3.29, 2.02, 3.41 fold in all tumors and BCLC stages A, B, and C, respectively; Fig. 1C). The differences in the FGFR1 mRNA levels between tumors and non-tumoral tissues were statistically significant only for BCLC stage A tumors (1.64 fold, P = 0.002) (Fig. 1A).
were not statistically significant (Fig. 1D). Up-regulation of mTOR also occurred in tumor tissues and was independent of BCLC stage (2.15, 1.89, 2.05, 3.88 fold in total, BCLC stages A, B, and C, respectively; Fig. 1E).

Characterization of the frequency and stage of actionable gene expression

Since overexpression is one of the mechanisms underlying activation of actionable molecules in cancers, we investigated the frequency of actionable gene overexpression in tumors. EGFR mRNA levels were up-regulated in 35.4% of the tumors and...
|        | EGFR | VEGFR2 | PDGFR | FGFR1 | mTOR |
|--------|------|--------|-------|-------|------|
| Low    | High | Low    | High  | Low   | High |
| Age    | 15   | 24     | 1     | 28    | 32   |
| Gender | Male | 5      | 8     | 10    | 5    |
|        | Female | 7      | 13    | 13    | 7    |
| HBV    | Absent | 4      | 14    | 13    | 4    |
|        | Present | 18     | 32    | 21    | 37   |
| HCV    | Absent | 5      | 11    | 9     | 11   |
|        | Present | 19     | 41    | 22    | 37   |
| Liver cirrhosis | Absent | 3      | 8     | 3     | 6    |
|        | Present | 1.2    | 26    | 1.4    | 33   |
| Child-Pugh class | A | 2.2    | 4.4    | 3.2    | 6.6   |
| BCLC stage | A | 10     | 31    | 0.049  | 14   |
| AFP level | <100 ng/ml | 10     | 29    | 2.267  | 11    |
|        | ≥100 ng/ml | 12     | 17    | 0.034  | 7    |
| Vascular invasion | Absent | 7      | 22    | 0.324  | 7    |
| Tumor number | Single | 11     | 41    | 0.001  | 17   |
| Tumor size | ≤5 cm | 3      | 32    | 0.038  | 13    |
|        | >5 cm | 15     | 41    | 0.043  | 14    |

Table 2. Relationships between mRNA expression of actionable molecules and clinicopathologic features.
up-regulation of PDGFR
VEGFR2 up-regulation was similar to that of EGFR (Fig. 2C).
regulation of EGFR was observed in 41.9% of the tumors at
molecules with HCC stage across the different BCLC stages. Up-
tumors irrespective of stage (Fig. 2E). mTOR was up-regulated in
64.7% of the tumors at BCLC stages A, B, and C, respectively
PDGFR was up-regulated in half of the tumors at a
high rate (61.5%). While patients with unchanged and down-regulated expression of FGFR1 were 40% and 35.4%, respectively,
only 24.6% of the patients showed up-regulation of FGFR1 in the tumors. mTOR was found to be up-regulated in half of the tumors (Fig. 2A).

We next examined the association of expression of actionable molecules with HCC stage across the different BCLC stages. Up-regulation of EGFR was observed in 41.9% of the tumors at BCLC stage A but the proportion decreased by 17.6% at later stages and down-regulation of EGFR was prominently found in advanced stage tumors (35.3%; Fig. 2B). The stage association of VEGFR2 up-regulation was similar to that of EGFR (Fig. 2C). Up-regulation of PDGFRβ was observed in 66.2%, 51.3%, and 64.7% of the tumors at BCLC stages A, B, and C, respectively (Fig. 2D). FGFR1 levels were up-regulated in about 20% of the tumors irrespective of stage (Fig. 2E). mTOR was found to be up-regulated in about half of the tumors in all the stages (Fig. 2F).

Association of clinical characteristics with actionable gene expression
To gain further insight into the gene expression of actionable molecules in HCC, the relationships between mRNA levels of actionable genes and clinicopathologic features were investigated. High mRNA expression of EGFR was correlated with the BCLC stage (P = 0.049, Table 2). The degree of tumor differentiation (Edmondson grade) was significantly associated with expression of both EGFR and VEGFR2 (P = 0.003 and 0.004, respectively), which showed that well-differentiated HCC tended to express EGFR and VEGFR2 at high levels. EGFR was significantly overexpressed in single tumors (P = 0.001).

Patient subtyping by clustering analysis of actionable gene expression
As molecular targeted therapy could be guided by the molecular subtypes reflecting the status of actionable molecules in individual tumors, we carried out a hierarchical clustering analysis to specify the patients harboring high levels of actionable genes.

Hierarchical cluster analysis revealed that the common expression patterns of EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR genes did not fall into distinct patient clusters significantly associated with BCLC stages (Fig S1). After categorization of BCLC stages, the hierarchical cluster analysis was performed to specifically classify the patients into subtypes according to the mRNA expression of actionable molecules. Patients with expression ratios of EGFR, VEGFR2, PDGFRβ, FGFR1, and mTOR at least twofold higher in tumors relative to non-tumors were clustered in subtype I at BCLC stages A, B, and C, respectively. In contrast, subtype II tumors that expressed all the genes at low levels were clustered in subtype II (Fig S3).

Since molecular targeted agents have multiple targets, molecular subtyping could not provide enough information for effectiveness of the drugs until it utilizes various markers. Tumors with up-regulation of sorafenib-targets VEGFR2 and PDGFRβ, which are hypothetically amenable to sorafenib, were classified in subtype I across the BCLC stages and the relative proportions of patients in each subtype gradually decreased toward BCLC stage C (a: 40.54%, b: 30.77%, c: 23.53%; Fig. 3B). In a, b, and c subgroups, the proportions of patients highly expressing VEGFR2 and FGFR1, who are expected to benefit from molecular targeted agents against VEGFR2 and FGFR1 including brivanib, were 22.73%, 10.26%, and 5.88%, respectively (Fig. 3C).

In the view of cross-talk between molecular targeted pathways and combination therapy under current clinical trials, VEGFR2 and PDGFRβ as sorafenib-target genes and other actionable genes were analyzed. Patients in subtype III at each stage exhibited down-regulation of EGFR and up-regulation of VEGFR2 and PDGFRβ. In addition, patients who overexpressed all the genes were classified in subtype I (Fig. 3D). Subtypes a, b, and c displayed up-regulation of VEGFR2 and PDGFRβ with mTOR for combined treatment of sorafenib and mTOR inhibitor (Fig. 3E).

Sorafenib sensitivity according to expression of sorafenib-target molecules in HCC cell lines
To verify whether the mRNA expression of targeted molecules is associated with the effectiveness of molecular targeted drugs, mRNA expression of sorafenib-target genes VEGFR, PDGFRβ, and c-Raf and in vitro sorafenib sensitivity were investigated in HCC cell lines. VEGFR2 was not expressed in any of the cell lines. While PDGFRβ mRNA was highly expressed in HepG2, there was relatively little expression in the other cell lines. Hep3B and HuH7, with the lowest expression of PDGFRβ, exhibited significantly higher expression of c-Raf compared to HepG2 and SK-Hep1. HepG2, which expressed PDGFRβ mRNA at a high level, showed relatively low mRNA expression of c-Raf (Fig. 4A). Whether the different mRNA levels of sorafenib-target molecules could affect the sensitivity of the HCC cells to sorafenib was examined. SK-Hep1, the cell lines with the lowest levels of both PDGFRβ and c-Raf, was the most resistant to sorafenib at concentrations lesser than 5 µM. On the contrary to SK-Hep1 cells, HepG2, HuH-7, and Hep3B with overexpression of PDGFRβ or c-Raf were more susceptible to the same concentration of sorafenib (Fig. 4B). These results were consistent with the cell viability results when cells were treated with 2.5 µM sorafenib in a time-dependent manner (Fig. 4C).

Discussion
Because of tumor selectivity and low toxicity, molecular targeted therapy is considered ideal for cancer patients. Since sorafenib was approved as the first-line treatment for advanced HCC, a number of molecular targeted drugs have been studied in clinical trials. However, the efficacy of targeted agents including sorafenib has proven to be modest and second-line therapies in combination with sorafenib have shown disappointing results [7,19].

Actionable molecular subtyping has been implemented for patient stratification in some types of cancer. Lung cancer has nine subtypes based on specific genetic aberrations including overex-
Figure 4. Analysis of mRNA expression of sorafenib-target genes and sorafenib sensitivity in HCC cell lines. (A) To examine the mRNA levels of VEGFR2, PDGFRβ, and c-Raf, real-time quantitative RT-PCR was performed with cDNA derived from SK-Hep-1, Hep3B, Huh-7 and HepG2 cell lines. Expression of the genes was plotted in bar graphs using $2^{-\Delta\Delta C^t}$ values of each gene and the significant difference in gene expression among the cells were marked with asterisk (*). (B, C) The susceptibilities of HCC cell lines to sorafenib treatment were evaluated by WST-1 cell viability assay. The significant differences between SK-Hep-1 and the other cells were marked with asterisk (*). (B) SK-Hep-1, Hep3B, Huh-7 and HepG2 cells were incubated for 24 hours at the indicated concentrations of sorafenib. (C) SK-Hep-1, Hep3B, Huh-7 and HepG2 cells were treated with 2.5 μM of sorafenib for the indicated time. After incubation in sorafenib-containing media, WST-1 was added to the cells for 2 hours and then the cell viabilities were measured.
pression and mutations [13] and melanoma is categorized into eight subtypes associated with targeted treatment [14]. Inspired by these approaches, we investigated for the first time expression of five major actionable molecules, EGFR, VEGFR2, PDGFRβ, FGF1, and mTOR in 130 HCC patients. Because measuring mRNA expression is more quantitative and reproducible, and feasible to implement as a multiplex analysis compared to measuring protein expression using methods such as IHC, and therefore real-time quantitative RT-PCR was used in this study.

mRNA levels of EGFR were significantly higher in tumors than in non-tumor tissues (Fig. 1A) and the overexpression rate was 35.4% (Fig. 2A). Our result is consistent with several prior studies that have demonstrated that EGFR is overexpressed in HCC [20]. Additionally, VEGFR2 and PDGFRβ were also highly expressed in HCC tumors (Fig. 1B and C), in accordance with previous reports [21,22]. Up-regulation of mTOR was more pronounced with the progression of HCC (Fig. 2F), which agrees with the results of Zhou, L et al [23]. Notably, a considerable number of tumors at BCLC stages A and B overexpressed the actionable molecules implying the applicability of molecular targeted treatment at an earlier stage in HCC. Taken together, our results demonstrating the overexpression of actionable molecules in early stages in addition to the advanced stage of HCC suggest that molecular targeted treatment at an earlier stage, along with adjuvant therapy, may be a new effective treatment strategy.

Traditionally, therapy decisions in HCC have been made according to the histologic features of tumors. However, due to the limitations of conventional classification systems in treatment decisions, molecular classes in HCC have been suggested by several research groups. The Mount Sinai-Barcelona-Milan-Broad Institute groups have proposed IGF-Akt-mTOR, Wnt-β-catenin, and IFN signaling pathways as major molecular classes in HCC [19]. Using global gene expression profiling, prognosis-associated genes have been categorized into subsets of HCC [24] and suggested as a classifier through a risk scoring method [25]. These approaches have characterized molecular subtypes of HCC but their validity in predicting the effectiveness of anti-cancer drugs has not yet been proven.

Actionable molecules have been recently utilized to classify HCC patients. VEGFR family and PDGFRα and β have been assessed as biomarkers to select HCC patients for targeted therapy by immunohistochemistry and tissue microarray [21,26]. Plasma biomarkers including VEGF were analyzed in SHARP trials [27]. Taking a different approach from previous studies, we stratified HCC with mRNA expression of actionable molecules directly associated with the targeted drug mechanism of action. The clustering method classified patients into subtypes with overexpression, down-regulation, and unchanged expression of actionable genes (Fig. 3). Since the efficacy of molecular targeted therapies has been better in patients with high expression of cognate molecules [11,28], patients in subtype aII, bII, and cII that highly express a set of VEGFR2-PDGFRβ or VEGFR2-FGFR1 may be susceptible to sorafenib or brivanib treatment, respectively. In contrast, subtypes aI, bI, and cI which had higher expression of the cognate actionable molecules in non-tumor rather than tumor tissues, would be more likely to have side effects without anti-tumor efficacy (Fig. 3B and C). To validate this supposition, we evaluated the responsiveness to sorafenib of human HCC cell lines showing differential expression of sorafenib-target genes. The complete absence of VEGFR2 expression in all HCC cell lines (Fig. 4A) is in line with previous reports showing primary expression of VEGFR2 in vasculature rather than tumor cells [29,30]. As expected, SK-Hep-1 having the lowest mRNA levels in both PDGFRβ and c-Raf (Fig. 4A) was the most resistant to sorafenib treatment in both a dose- and time-dependent manner (Fig. 4B and C). In contrast, Hep3B and Huh7, who had a PDGFRβ mRNA expression level as low as SK-Hep-1 but high expression of c-Raf, another sorafenib target molecule (Fig. 4A), are both sensitive to sorafenib (Fig. 4B and C). These results clearly demonstrated that overexpression of either sorafenib-target gene confers susceptibility to sorafenib treatment in HCC. Taken together, our results suggest that actionable molecular subtyping by mRNA expression analysis could be a potent strategy for stratification of HCC patients amenable to molecular targeted therapy.

Low responsiveness to sorafenib in HCC could be ascribed to resistance mechanisms separate from those attributable to low expression of the molecular targets of sorafenib. Although mutation in drug target genes is one of the major causes for drug resistance in many types of cancer, mutations in actionable molecules have been uncommon in HCC, for example, EGFR activating mutations have been reported to occur in 0~1% of HCC [31,32] and RAF mutations have never been described in HCC [33]. The EGFR pathway is one of the mechanisms underlying sorafenib resistance. An in vitro study revealed that EGFR pathways are activated in HCC cells with resistance to sorafenib [34,35]. These cells are more susceptible to sorafenib treatment when it is combined with the EGFR inhibitor gefitinib than when treated with sorafenib alone or gefitinib alone. Contrary to this result, another EGFR inhibitor, erlotinib, showed little anti-tumor activity and no synergistic effect upon co-treatment with sorafenib in a rat model of HCC [36]. To address the issue of combination therapy, we categorized HCCs according to the mRNA expression of molecules inhibited by combination therapy under clinical trials. Considering that EGFR activation causes sorafenib resistance, subtype III showing low expression of EGFR with high levels of VEGFR2 and PDGFRβ may be sensitive to sorafenib whereas subtype I with all the molecules up-regulated may be resistant to sorafenib treatment (Fig. 3D). Interestingly, mRNA expression of EGFR moderately correlated with those of VEGFR2 and PDGFRβ, supporting the potential effectiveness of combined treatment with an EGFR inhibitor and sorafenib as shown in previous reports [34,35]. However, it should be determined in clinical trials whether up-regulation of EGFR is beneficial or not in sorafenib or combination treatments. Further clustering results indicated that most of the tumours overexpressing mTOR (subtypes a, b, and c) also highly expressed VEGFR2 and PDGFRβ (Fig. 3E), which strongly supports a potential synergistic effect of the mTOR inhibitors combined with sorafenib in HCC [37–39]. Additionally, this result implies that combined treatment with sorafenib plus mTOR inhibitor could help overcome both sorafenib and rapamycin resistance [38,40]. Taken together, our findings provide molecular evidence that combined treatment of molecular targeted agents may be reasonable in HCC patients.

To our knowledge, we stratified for the first time HCC patients according to the mRNA expression of actionable molecules. Our findings provide the rationale for a new treatment strategy based on companion diagnostics toward molecular targeted therapy in
HCC and warrant further investigation in prospective clinical trials.

Supporting Information

Figure S1 Hierarchical clustering analysis of 5 actionable genes. Each row and column means an individual gene and an individual patient sample, respectively. The patients were ordered by Euclidean distance and linkage according to the ratios of $2^{-\Delta\text{Ct}}$ values in each tumor compared to the cognate no-tumor. In the heat map, the red and green color reflect high and low expression levels, respectively, as depicted in the scale bar at the bottom. The scale represents the gene expression ratios from 4 to $-4$ in fold difference of $2^{-\Delta\text{Ct}}$ values.

Table S1 Sequences of primer and probes used in this study.

Acknowledgments

We appreciate Dr. Lewis R. Roberts (Mayo Clinic) for critical review of the manuscript.

Author Contributions

Conceived and designed the experiments: JHK JYP YHM HJW GK. Performed the experiments: YSY JPK NL JHS. Analyzed the data: JHK YSY NL Dong-Sik Kim KJH YHM HJW. Contributed reagents/materials/analysis tools: JWJ Daeh Shick Kim KYC HJW. Wrote the paper: JHK YHM HJW.

References

1. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 7: 448–458.
2. Villanueva A, Llovet JM (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology 140: 1410–1426.
3. Llovet JM, Real FX, Roncalli CA, Mazarrasa V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378–390.
4. Cheng AL, Kang YK, Chen Z, Tao CQ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 23–34.
5. Zhu AX (2012) Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol 39: 493–502.
6. Huynh H (2010) Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 80: 550–560.
7. Villanueva A, Llovet JM (2012) Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin Cancer Res 18: 1024–1026.
8. Ziegler A, Koch A, Krockenberger K, Groschedig A (2012) Personalized medicine using DNA biomarkers: a review. Hum Genet 131: 1627–1638.
9. Williams PM, Living TL, Jessup JM, Conley BA (2012) Bridging the gap: moving predictive and prognostic assays from research to clinical use. Clin Cancer Res 18: 1531–1539.
10. Poste G, Carbone DP, Parkinson DR, Verweij J, Hewitt SM, et al. (2012) Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res 18: 1515–1523.
11. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.
12. Lynch TJ, Bell DW, Sordella R, Giri D, Ang裔ken S, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139.
13. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, et al. (2012) A novel classification of lung cancer into molecular subtypes. PLoS One 7: e31906.
14. Vidwans SJ, Schleery KT, Fisher DE, Tenebaum JM, Travers MD, et al. (2012) A melanoma molecular disease model. PLoS One 8: e6825.
15. Forster A, Reig M, De Lope CR, Brux J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30: 61–74.
16. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462–503.
17. Zhou L, Huang Y, Li J, Wang Z (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27: 255–261.
18. Lee JS, Chiu IS, Heo J, Calvisi DF, Sun Z, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667–676.
19. Kim SM, Leem SH, Chiu IS, Park YY, Kim SC, et al. (2012) Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55: 1443–1452.
20. Jia JB, Zhang PY, Sun HC, Zhang JB, Zhang W, et al. (2009) Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 135: 847–854.
21. Llovet JM, Pena CE, Lahlou CD, Shm M, Meinhardt G, et al. (2012) Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18: 2290–2300.
22. O'Brien SG, Guillot F, Larson RA, Gathmann I, Baccarani M, et al. (2005) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-Phase chronic myeloid leukaemia. N Engl J Med 353: 994–1004.
23. Morelli MP, Brown AM, Pitts TM, Tendler J, Ciardiello F, et al. (2009) Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther 8: 2546–2558.
24. Smith NR, Baker D, James NH, Ralchile J, Jenkins M, et al. (2010) Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 16: 3548–3561.
25. Su MC, Lien HC, Jeng YM (2005) Absence of epidermal growth factor receptor-1 and -3 mutations in 1021 mutation in hepatocellular carcinoma. Cancer Lett 224: 117–121.
26. Nault JC, Zucman-Rossi J (2011) Genetics of hepatobiliary carcinogenesis. Semin Liver Dis 31: 173–187.
27. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhmann D, et al. (2003) Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52: 706–712.
28. Bluvet-Van Enggelpoel MJ, Chetouh F, Fanoux L, Aoudjehane L, Barbis V, et al. (2012) Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57: 108–113.
29. Ezekytuk Z, Louandre C, Trecherel E, Godin C, Chauffert B, et al. (2012) EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131: 2961–2969.
30. Siegert W, Pinter M, Dauser B, Rohr-Udolov N, Piquet AC, et al. (2012) Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma. J Hepatol 57: 392–399.
31. Gedaly R, Angulo P, Hunsley J, Daily MF, Chen C, et al. (2010) PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 30: 4951–4958.
32. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, et al. (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 13: 2673–2683.
33. Newell P, Toftanin S, Villanueva A, Chiang DY, Minguet B, et al. (2009) Ras pathway activation in hepatocellular carcinoma and anti-tumor effect of combined sorafenib and rapamycin in vivo. J Hepatol 51: 725–733.
34. Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, et al. (2008) Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 14: 5124–5130.

PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e64260